Journal
TRENDS IN CANCER
Volume 9, Issue 10, Pages 840-854Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2023.06.009
Keywords
-
Categories
Ask authors/readers for more resources
The field of metastatic prostate cancer has witnessed significant therapeutic advances in the past decade, with recent approvals of triplet therapy regimens and combination therapies. However, treatment selection and sequencing remain challenging.
The field of metastatic prostate cancer (mPCa) has seen unprecedented therapeutic advances in the past decade. In the past 2 years, recent approvals include the triplet therapy regimens of androgen deprivation therapy (ADT), docetaxel, and an androgen receptor (AR) pathway inhibitor (ARPI) in the castrationthe combination of poly(ADP) ribose polymerase (PARP) inhibitors (PARPis) and ARPIs in the castration-resistant setting. With many agents currently undergoing investigation in registration trials, the therapeutic armamentarium will expand rapidly, making treatment selection and sequencing challenging. Herein, we review the landmark clinical trials ongoing or reported in the past 2 years, discuss the optimal approach to treatment selection, and provide insight into future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available